Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells.

[1]  P. Stern,et al.  Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma , 2010, Clinical Cancer Research.

[2]  T. Gajewski,et al.  Costimulatory and coinhibitory receptors in anti‐tumor immunity , 2009, Immunological reviews.

[3]  A. Chang,et al.  FOXP3 defines regulatory T cells in human tumor and autoimmune disease. , 2009, Cancer research.

[4]  B. Redman,et al.  Phase I/II trial of tremelimumab in patients with metastatic melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T. Abraham,et al.  Inducible reprogramming of human T cells into Treg cells by a conditionally active form of FOXP3 , 2008, European journal of immunology.

[6]  L. Zitvogel,et al.  CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab? , 2008, Clinical Cancer Research.

[7]  B. Kavanagh,et al.  CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. , 2008, Blood.

[8]  J. Drijfhout,et al.  CD4+ T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25+ T cells , 2008, Cancer Immunology, Immunotherapy.

[9]  Nitin J. Karandikar,et al.  Transient regulatory T-cells: a state attained by all activated human T-cells. , 2007, Clinical immunology.

[10]  F. Hodi,et al.  Well-Defined Melanoma Antigens as Progression Markers for Melanoma: Insights into Differential Expression and Host Response Based on Stage , 2006, Clinical Cancer Research.

[11]  B. Comin-Anduix,et al.  Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Rosenberg,et al.  Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade , 2005, The Journal of Immunology.

[13]  S. Rosenberg,et al.  Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[15]  J. Yates,et al.  Differential expression of CTLA‐4 among T cell subsets , 2004, Clinical and experimental immunology.

[16]  P. Leibson.  The regulation of lymphocyte activation by inhibitory receptors. , 2004, Current opinion in immunology.

[17]  D. Schadendorf,et al.  Tissue expression and sero-reactivity of tumor-specific antigens in colorectal cancer. , 2004, Cancer letters.

[18]  C. Thompson,et al.  T-cell regulation by CD28 and CTLA-4 , 2001, Nature Reviews Immunology.

[19]  J. Egen,et al.  CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. , 2001, Annual review of immunology.

[20]  Fiona Powrie,et al.  Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation , 2000, The Journal of experimental medicine.

[21]  V. Reuter,et al.  Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[23]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[24]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.

[25]  J. Allison,et al.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.

[26]  P. Linsley,et al.  Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. , 1994, Immunity.

[27]  P. Linsley,et al.  CTLA-4 can function as a negative regulator of T cell activation. , 1994, Immunity.